| Name | Title | Contact Details |
|---|---|---|
Jeff Sidell |
Chief Technology Officer | Profile |
Eric Whitford |
IT Director | Profile |
Nitin Uplekar |
Chief Information Officer | Profile |
Jonathan Shough |
President of Technology Solutions | Profile |
RESULTS ARE IN OUR DNA Fostering partnerships within the Life Science industry to enable innovation and positive outcomes. CLIENTS JOB SEEKERS Company We Are Precision Life Sciences Precision Life Sciences, a WBE (Woman-Owned Business Enterprise), was ...
Kleo Pharmaceuticals is advancing the field of immunotherapy by developing small molecules that emulate biologics.
Were reimagining how technology can solve #stroke`s unmet needs, enabling providers with the ability to raise the standard of care for patients.
Were one of the world’s leading providers of high quality, empty, hard capsules serving global pharmaceutical and dietary supplement markets.
XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.